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INTRODUCTION
The beneficial effect of functional food and some of its 
components on the consumer health have been studied [1,2]. 
The primary objective of functional foods is to improve, 
maintain and enhance the health of consumers through the 
alimentation [3]. Among the foods with functional claims are 
those added with probiotic microorganisms [4]. Probiotics are 
live microorganisms that when continuously administered 
in adequate amounts, confer benefits to the health of the 
consumer [5]. The main action mechanisms of probiotics 
include competition for sites of adhesion, antimicrobial activity, 
neutralization of undesirable compounds [enterotoxins, 
ammonia, toxic biogenic amines], alteration of metabolism 
[aid in digestion, reduction of precarcinogenic enzymes], and 
increase of immunity [increased lymphocyte and macrophage 
activity] [6]. However, it is important to emphasize that 
these mechanisms of action attributed to the probiotics 
are species-specific, i.e., the same strain cannot be able to 
exert all these health benefits simultaneously [4,7,8]. In this 
sense, bifidobacteria stands out for being one of the majority 
members of the Actinobacteria class that inhabit the human 
gut [9]. Due to this characteristic, bifidobacteria strains are 
chosen for to be used in a wide range of food products in order 
to be delivered in the gut and, thus, exert their beneficial 
effects [4].
One of the significant challenges in developing a probiotic 
product with Bifidobacterium is to ensure a high survival 
rate of the bacteria during the passage through the human 
gastrointestinal tract [4,10,11]. The main obstacles for 
bifidobacteria are the extreme acid pH in the stomach and the 
high bile salt concentrations presence from the duodenum to the 
ileum [12]. However, these class of bacteria has the intrinsical 
advantage to accommodate their enzymatic machinery 
to survive along the passage through the gastrointestinal 
system [13]. In this way, due to this adaptive capacity, the 
bifidobacteria can change some metabolic/functional routs 
which causes an improved capacity to survive and colonize the 
gut [13].
When Bifidobacterium ssp. arrives alive until the large 
intestine, the probiotic bacteria present several mechanisms 
of action to adhere to the epithelium and also inhibit bacterial 
pathogens [14]. The mechanisms involved in this antibacterial 
activity is the ability of bifidobacteria to product inhibitory 
substances, inhibit the pathogen adhesion to surfaces and 
produce iron-siderophore [15]. Bifidobacterium spp. produce 
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some inhibitory substances such as bacteriocins, hydrogen 
peroxide, and lactic and acetic acids that are effective in 
inhibiting the growth of several pathogenic bacteria [16]. 
Therefore, another important factor that influence the greatly 
ability of bifidobacteria strains to inhibit the pathogens is their 
adherence to the intestinal mucosal surface and consequently 
the colonization of the gut [17]. The iron-siderophore 
production, used for the uptake of lactoferrin or transferrin 
by microorganisms, is also a mechanism to inhibit the survival 
of pathogenic bacteria [18]. Thus, the main goal of this work 
is to provide an overview of the current developments of 
bifidobacteria specific characteristics of survive passage through 
the gastrointestinal system and inhibit pathogenic bacteria in 
the intestine.
BIFIDOBACTERIA AS PROBIOTIC
Specific criteria are used in order to select a microorganism to be 
used as probiotic. These bacteria must be acid and bile tolerant, 
nonpathogenic, no transferable antibiotic resistance and present 
in the normal healthy gut microbiota. Also, they could produce 
some antimicrobial substances against pathogenic bacteria, 
be genetically stable (identified by appropriate molecular 
techniques) and adhere to intestinal mucosa (mucus and 
enterocytes) [19]. Moreover, one of the most important safety 
aspects of the use of probiotics includes a history of being non-
pathogenic and a history of no association with diseases [20]. 
The bioavailability of nutrients, the production of antimicrobial 
compounds, improvement of motility, relieving of intestinal 
constipation as well the decrease of Helicobacter pylori infection 
in the stomach are also attributed to the consumption of 
probiotic bacteria [21,22].
In food products, one of the most used probiotic cultures is 
those of the genus Bifidobacterium [23–25]. Microorganisms 
of the genus Bifidobacterium are gram-positive, non-spore 
forming bacilli, without motility, catalase negative, and some 
strains develop branches morphologically appearing with 
bifidopartide form [26,27]. Most bifidobacteria survives only 
in anoxic conditions, however, some species can survive in 
aerobic conditions or tolerate oxygen in the carbon dioxide 
presence [28]. Bifidobacterium can grow in the temperature 
range of 25–45 ºC, with the optimum temperature between 
36 and 38 ºC for growth of human origin Bifidobacterium. 
Bifidobacteria are demanding in relation to the pH values, which 
are around 6.5–7.0, with no growth below 4.5 or above 8.5 [22]. 
Most Bifidobacterium species produce vitamins such as thiamine 
(B1), riboflavin (B2), pyridoxine (B6), folic acid (B9), cobalamin 
(B12), ascorbic acid ©, nicotinic acid (PP) and biotin [29]. The 
principal strains of Bifidobacterium used for commercial purpose 
or studied in vitro and humans are summarized in Table 1.
For the beneficial effects associated with probiotic consumption 
to be achieved, these should be in appropriate quantities in 
the food and must be consumed daily [4]. Therefore, the 
recommended minimum daily intake is around 8-9 log Colony 
Forming Units (CFU g-1 or mL-1), which can be achieved with 
daily consumption of at least 100g of a 6-7 log Colony Forming 
Units (CFU g-1 or mL-1 of the product) [24]. Compensation for 
possible losses during food processing and storage as well as loss 
during passage through the gastrointestinal tract may directly 
influence this count [30]. However, factors such as high levels 
of oxygen, pH, acidity, time and temperature of storage and 
processing cause sensitivity and directly affect the viability of 
bifidobacteria [31,32].
TOLERANCE OF BIFIDOBACTERIA TO 
GASTROINTESTINAL CONDITIONS
In order to exert the beneficial effects on the host, it is necessary 
that the probiotic microorganisms can overcome intact the 
human digestive system [27]. Since the effects of probiotics 
are related to their activity in the digestive tract, and these 
depend on their colonization and survival in this environment, 
these bacteria must be resistant to the physiological and 
physicochemical processes of the gastrointestinal system. 
For Naidu et al. [33], probiotic bacteria must survive passage 
through the mouth, esophagus, stomach (pH 2), and small 
intestine to exert their benefits in the gut. Thus, they should 
be able to survive through gastric juice (hydrochloric acid), 
pancreatic juice and bile salts, i.e. surviving in acidic (stomach) 
and basic (duodenum) conditions [34].
Several stress conditions influenced the survival of probiotics 
during the passage through the gastrointestinal system [35]. 
Although the loss of bacterial viability occurs throughout all 
the digestive process, the greater losses are reported to the 
stomach, due to its acidity, and the presence of bile salts in the 
duodenum [36]. In the stomach, many strains of Bifidobacterium 
ssp. intrinsically lack the ability to survive such acidity. In general, 
the acid tolerance of bifidobacteria may be considered weak, 
except Bifidobacterium lactis and Bifidobacterium animalis [37]. 
Sánchez et al. [38] reported that the survival of bacteria 
lacking a respiratory chain, such as Bifidobacterium BB-12, is 
associated with their F0F1-ATPase enzyme ability to maintain the 
intracellular pH under acidic conditions. Due to the damaging 
effects, even if probiotics are still viable in the stomach, upon 
reaching the colon, they may be in a sub-lethally injured state. 
Thus, their chances of survival may be compromised, along with 
their ability to colonize the intestine and have an advantageous 
effect on the host [35]. This behavior can be attributed to 
the low pH value in the stomach (~2) and the presence of 
pepsin [39,40]. Also, Matsumoto et al. [37] affirm that the 
acid tolerance of probiotic bacteria depends on factors such as 
growth medium, incubation conditions, enzymes profile and 
cytoplasmic membrane composition of each strain.
After exposure to the stomach conditions, the probiotic 
bacteria reaches to the small intestine and are submitted to the 
duodenum (i.e., bile salts, pancreatin and pH approx. 5.0) up 
to the ileum conditions [41]. The bile salts are known for their 
antimicrobial activity against probiotic bacteria, mainly due to 
their amphiphilic nature and ability to dissolve the bacterial 
cellular membrane [42]. Also, Kurdi et al. [43] observed that the 
bile salts cumulate in the bacterial cytoplasm, causing disturbs 
on membrane integrity and therefore the cell death. As observed 
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by Vinderola and Reinheimer [44], the survival of probiotic in 
bile environment depends on the concentration of bile, exposure 
time and bacterial species and strains. Moreover, the survival 
of probiotic strains in the gastrointestinal tract might not only 
depend on their number and physiological state but also on 
the food matrix and food consumption habits that affect bile 
excretion [45]. Aspects such as amount and type of protein and 
fat, pH, presence of specific carbohydrates or other ingredients 
may also influence the resistance of probiotics during passage 
through the gastrointestinal tract [46–49]. Begley et al. [50] 
also stated that some components of the food might bind to 
bile salts, which would protect the probiotic bacteria from 
their toxicity.
After passage through the stages of the stomach and duodenum, 
another essential aspect about probiotic bacteria is their ability 
to adhere to the epithelial surface and colonize the small 
intestine or colon [51]. The hydrophobic bacterial surface is 
essential for the interaction between the intestinal glycoprotein 
layer, the receptor on the intestinal epithelial cell and fatty acid 
binding sites [52]. Also, the presence of prevailing apolar groups 
of bifidobacteria membrane may also support the cell adherence. 
As observed by Wang et al. [53], the surface hydrophobicity 
of B. animalis BB-12 was 50%. However, the adhesion ability 
varies with the type of Bifidobacterium, strain and the previous 
damages suffered [51]. Also, it must be highlighted that Lee 
et al. [54] showed for an inflammatory bowel disease that the 
better efficacy of the treatment was strongly dependent by 
using milk as a carrier medium. Their results strongly indicate 
that dairy products might be the preferred delivery matrix for 
probiotic strains for benefiting human health.
In light of these observations, to evaluate the survival of 
probiotics during and after the ingestion process, in vitro 
gastrointestinal simulation methodologies are being used 
as a rapid and straightforward approach in place of in vivo 
assays, since the latter are expensive long-term studies with 
high variability between individuals [55]. In vitro studies 
can provide useful insights on probiotic action, safety, and 
efficacy of probiotics targeted for human use [45]. Several 
studies have conducted in vitro gastrointestinal trials and 
evaluated the survival of probiotics in foods [34,46,48,56–59], 
but not continuously as naturally occurs during digestion. For 
that reason, evaluation of gastrointestinal tolerance by these 
methods may not satisfactory predict the in vivo survivability 
of probiotics accompanied by the food matrix [60]. Thus, 
Madureira et al. [42] recommend the use of a continuous in vitro 
gastrointestinal model that includes all compartments of the 
gastrointestinal tract (mouth, esophagus-stomach, duodenum, 
and ileum). This method also includes the presence of enzymes 
(α-amylase, pepsin, and pancreatin) and bile salts, mechanical 
simulation of peristaltic movements, time retention and also a 
pH gradient in the stomach. By using this methodology, Verruck 
et al. [39] verified the protective effect of a buffalo Minas fresh 
cheese on Bifidobacterium BB-12 survival. Pinto et al. [61] 
using spray drying method, verified that the use of sweet whey 
and inulin as encapsulating agents provided better protection 
to the bifidobacteria when compared with the free cells after 
exposure to these simulated gastrointestinal conditions. 
Holkem et al. [32] demonstrated that Bifidobacterium BB-12 
resists better to the passage through simulated gastrointestinal 
fluids and under acid conditions when the technique of 
emulsification/internal ionic gelation for encapsulation was 
used. This in vitro simulated gastrointestinal conditions protocol 
was also successfully used by Almeida et al. [62], Pinto et al. [63] 
and Verruck et al. [40] for probiotic mascarpone-type cheese, 
greek yogurt, and microcapsules with full-fat goat’s milk and 
prebiotics, respectively. Therefore, extrapolation of data from 
closely related strains is not acceptable, thus, each product and 
strain should be tested and documented independently [45]. 
So, the protocol proposed by Madureira et al. [42] may be used, 
giving us a safe view of what happens to the probiotic bacteria 
viability after the passage through the gastrointestinal system.
MECHANISMS OF ACTION OF PROBIOTICS FOR 
PATHOGENIC BACTERIA INHIBITION
The gastrointestinal tract is one of the access ways of pathogens, 
and if the defense mechanisms fail, these pathogens can 
colonize and/or penetrate the cells and tissues of the host [64]. 
As summarized in Figure 1, probiotic can inhibit the growth of 
pathogenic bacteria in the gut by several mechanisms, such as 
the capacity to synthesize antibacterial substances, inhibit the 
adhesion of pathogenic bacteria on the intestinal surface and 
also produce iron-siderophores [15]. Siró [45] reported that 
probiotics, such as Lactobacillus spp. and Bifidobacterium spp., 
have developed different mechanisms to survive in competition 
with pathogenic bacteria. In the case of Bifidobacterium spp., 
one of their important proprieties is the ability to produce 
organic acids (e.g., lactic and acetic acids), hydrogen peroxide 
and bacteriocins to suppress the colonization of pathogenic 
bacteria in the gut [22]. Makras and De Vuyst [65] tested 37 
Bifidobacterium strains, including Bifidobacterium animalis 
subsp. lactis BB12, and reported a great organic acids production 
Table 1: Probiotic Bifidobacterium strains used in commercial products or studied in vitro and humans.
Strain Benefits
B. breve NCIMB8807 Reduces symptoms of irritable bowel syndrome, reduces gastrointestinal cancer possibilities, eradication of Campylobacter jejuni 
in children
B. longum BB536 Enhance intestinal function in premature infants>1000g
B. longum BL04‑3008 Decrease of azoxymethane with reduction of gastrointestinal cancer possibilities
B. lactis DR10 Reduction of E. coli in the gastrointestinal tract
B. animalis spp. lactis BB12 Prevention of traveler’s diarrhea, treatment of viral diarrhea including rotavirus diarrhea, modulation of intestinal flora, 
improvement of constipation, modulation of immune response, atopic dermatitis symptoms alleviation in children
B. animalis DN‑173 010 Increase bowel motility and reduce diarrhea caused by rotavirus
Adapted from Lerayer et al.[6] and Saarela et al. [20].
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with a decrease in the medium pH. This behavior led to the 
inhibition of Salmonella enterica ser. Typhimurium SL1344 and 
Escherichia coli C1845.
Although the antimicrobial effect of the Bifidobacterium is often 
ascribed to the inhibitory action of organic acids and the related 
pH decrease in the bowel, the bifidobacteria has a high potential 
as bacteriocins producers [66]. Bacteriocins are ribosomally-
synthesized peptides that have antimicrobial activity against 
other bacteria by creating pores in the cellular membrane 
causing the dissipation of proton motive force, ATP depletion, 
and leakage of nutrients that subsequently lead to cell damage 
or cell death [67]. Fung et al. [15] stated that numerous genera 
of pathogenic and nonpathogenic bacteria might be affected by 
bacteriocins. However, as cited by Lima et al. [68], the efficacy of 
probiotic bacteria against pathogens is based on a combination 
of bacteriocin action and production of antimicrobial substances 
such as hydrogen peroxide and organic acids. The antagonistic 
activity of Bifidobacterium lactis BB12 and Bifidobacterium 
longum 46 against six target pathogens was evaluated using 
different assays (liquid and solid media, microaerobic and 
anaerobic cultivation) and high activity against Shigella sonnei 
and E. coli was reported [69]. Gibson and Wang [70] reported 
that bactericidal or bacteriostatic substances were excreted by 
eight strains of bifidobacteria and could inhibit the growth of 
Salmonella spp., E. coli, Listeria monocytogenes, Campylobacter 
spp., S. sonnei and Vibrio cholerae. Martins et al. [71] reported 
production of antagonistic substances by Bifidobacterium 
BB12 against Bacillus cereus, Clostridium difficile, Clostridium 
perfringens Type A, E. coli ATCC 4328, Enterococcus faecalis, 
L. monocytogenes, Pseudomonas aeruginosa, S. Typhimurium, 
Salmonella Typhi, Shigella flexneri, S. sonnei, and Candida 
albicans. The better ability to colonize the gastrointestinal 
tract of mice is linked to higher hydrophobic property of the 
cell wall of Bifidobacterium BB12. Also, Saleh and El-Sayed [72] 
reported two bacteriocins: bifilact Bb-12 and bifilong Bb-46, the 
first produced by Bifidobacterium lactis Bb-12 and the second 
by B. longum Bb-46. These bacteriocins shown strong activity 
against Staphylococcus aureus, S. Typhimurium, Bacillus cereus 
and E. coli.
As the colonization of the gastrointestinal tract is based on the 
ability of the bacteria to adhere to the intestinal epithelium, 
another vital factor in the competitive exclusion of pathogenic 
bacteria is the ability of the probiotics to adhere to the mucosal 
surface [20]. Collado et al. [73] reported in an in vitro study 
that Bifidobacterium BB-12 was able to adhere to the intestinal 
mucosa and inhibit several pathogens, such as Bacteroides 
vulgatus, Clostridium histolyticum, C. difficile, Enterobacter 
aerogenes, L. monocytogenes, S. Typhimurium, and S. aureus. 
Bernet et al. [74] reported that bifidobacteria isolated from 
human gastrointestinal tract were able to adhere to Caco-2 cells 
due to the presence of a proteinaceous adhesion-promoting 
factor which affected the adherence of pathogenic E. coli 
and S. Typhimurium. In another study, Collado et al. [75] 
investigated the protective effect of Bifidobacterium lactis Bb12 
and Lactobacillus rhamnosus LGG alone and in combination 
on the adhesion of S. Typhimurium, C. perfringens, C. difficile, 
and E. coli K2. They demonstrated that in combination, the 
probiotic strains enhanced each other’s adhesion, mainly in 
pig large intestinal mucus and reduced the adhesion of all the 
tested pathogens. Additionally, Jungersen et al. [7] affirmed 
that Bifidobacterium BB-12 is able to compete for mucosal 
adhesion and, thus, inhibit serious gastrointestinal pathogens 
by antimicrobial substances production.
Beyond the capacity of producing antimicrobial substances and 
inhibit the adhesion of pathogenic bacteria, the production of 
iron-siderophores was also reported as an antimicrobial ability 
of probiotics [15]. In general, the iron plays a vital role in the 
metabolism of bacteria that requires iron for growth acting as a 
global regulator of gene expression [76]. To obtain the necessary 
iron to survive, bacteria developed several metabolic routes to 
excel over other lineages. One of their approach is to synthesize 
and export siderophores, which are chelators with high-affinity 
to iron [77]. Certain bacteria or fungi produce and release 
siderophores to scavenge extracellular iron and redeliver the 
metal to the cell [78]. Vazquez-Gutierrez et al. [79] evaluated 
the siderophore production of 86 bifidobacteria strains (30 
from culture collections and 56 isolates from infants) and 
reported that 35 strains exhibited high siderophore activity, 31 
showing intermediate and 20 low activity. They conclude that 
the mechanisms used by bifidobacteria to sequestrate and use 
iron confers an great advantage to their survival and competition 
agaist pathogenic bacteria.
CONCLUSIONS
Bifidobacteria strains are used in a wide range of food products 
in order to be delivered in the gut for exert their beneficial 
effects.however, these strains have some obstacles to overcome, 
as survive through the acid pH in the stomach  the presence of 
high bile salt concentrations in the intestine. However, when 
these bacteria arrives alive until the large intestine, several 
mechanisms of action to inhibit pathogenic bacteria are 
present, i.e., production of inhibitory substances, inhibition 
of the pathogen adhesion to surfaces and production of iron-
siderophores. In the light of these observations, this concise 
review showed the necessary theoretical background and 
Figure 1: Summary of antibacterial activities of bifidobacteria. Adapted 
and modified from Fung et al.[15]
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some details about survival during the passage through the 
human gastrointestinal system and mechanisms of actions of 
bifidobacteria against pathogenic bacteria.
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